BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18670243)

  • 1. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V
    Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High plasma clozapine levels in tardive dyskinesia.
    Pollack S; Lieberman J; Kleiner D; Szymanski S; Kane J; Borenstein M; Cooper T
    Psychopharmacol Bull; 1993; 29(2):257-62. PubMed ID: 8290674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia.
    Lerner V; Miodownik C; Kaptsan A; Vishne T; Sela BA; Levine J
    J Clin Psychiatry; 2005 Dec; 66(12):1558-63. PubMed ID: 16401157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose vitamin B6 decreases homocysteine serum levels in patients with schizophrenia and schizoaffective disorders: a preliminary study.
    Miodownik C; Lerner V; Vishne T; Sela BA; Levine J
    Clin Neuropharmacol; 2007; 30(1):13-7. PubMed ID: 17272965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Lerner V; Cohen H; Kotler M
    Clin Neuropharmacol; 2000; 23(4):212-5. PubMed ID: 11020126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C; Cohen H; Kotler M; Lerner V
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia.
    Mosnaim AD; Wolf ME
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):27S-30S. PubMed ID: 2906066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel.
    Lerner V; Libov I; Kaptsan A; Miodownik C; Dwolatzky T; Levine J
    Isr J Psychiatry Relat Sci; 2007; 44(1):20-8. PubMed ID: 17665807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pro- and antioxidant processes in schizophrenics with tardive dyskinesia].
    GaƂecki P; Pietras T; Florkowki A
    Psychiatr Pol; 2005; 39(6):1131-41. PubMed ID: 16526180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pyridoxal 5'-phosphate is a significant indicator of immune responses in the mechanically ventilated critically ill.
    Huang YC; Chang HH; Huang SC; Cheng CH; Lee BJ; Cheng SY; Su KH
    Nutrition; 2005; 21(7-8):779-85. PubMed ID: 15975484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Tan YL; Zhou DF; Zhang XY
    Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia.
    Kang SG; Lee HJ; Choi JE; An H; Rhee M; Kim L
    Hum Psychopharmacol; 2009 Jan; 24(1):55-60. PubMed ID: 19051221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia and plasma homovanillic acid.
    Moore DC; Glazer WM; Bowers MB; Heninger GR
    Biol Psychiatry; 1983 Dec; 18(12):1393-402. PubMed ID: 6140961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of acute prolonged starvation on the concentrations of vitamin B6 aldehyde derivatives in whole blood.
    Barnard HC; Vermaak WJ; Potgieter GM
    Int J Vitam Nutr Res; 1986; 56(4):351-4. PubMed ID: 3804610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semi-automated fluorometric determination of pyridoxal-5'-phosphate (vitamin B6) in whole blood by high-performance liquid chromatography (HPLC).
    Schrijver J; Speek AJ; Schreurs WH
    Int J Vitam Nutr Res; 1981; 51(3):216-22. PubMed ID: 7319721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of pyridoxal 5'-phosphate in patients with cystic fibrosis.
    Faraj BA; Caplan DB; Camp VM; Pilzer E; Kutner M
    Pediatrics; 1986 Aug; 78(2):278-82. PubMed ID: 3737304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.